Bmtcn

BMTCN Allo HSCT with T-cell depleted graft - ✓ ✓ What type of transplants commonly have PTLD as a secondary malignancy? alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan, ifos), radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide, mitoxantrone)✓✓ acute leukemia and MDS Therapies associated with therapy-related neurofibromatosis type 1, Fanconi anemia - ✓✓ Genetic predispositions that increase risk of primary and secondary cancers T-cell depleted graft, mismatched related or unrelated donor. Busulfan, ATG, mAbs, TBI patient w/ primary immunodeficiency, acute or extensive GVHD, EBV -✓✓ Risk factors for PTLD younger age at HSCT, TBI, chronic GVHD, increasing time from transplant, infections, genetic predisposition, lifestyle factors -✓✓ Risk factors for secondary solid tumors EBV-specific cytotoxic T cells, mAbs targeted to B cells (rituximab), combination chemotherapy - ✓ Treatment options for PTLD conventional chemo or allo transplant. Poor outcomes.✓✓ Treatment options for secondary MDS/acute leukemia Physical, Functional, Psychological, Social, Spiritual/existential, Multiple interactions between domains - ✓ ✓ QOL domains damage to the hypothalamic-pituitary-gonadal axis: elevated FSH, elevated LH, low testosterone levels; cavernosal arterial insufficiency causing ED -✓✓Altered sexual health in male HSCT